CTLA4 and cancer: Ipilimumab, a humanized CTLA-4 monoclonal antibody, was the first ICI approved by the FDA and remains a cornerstone of cancer immunotherapy, particularly for unresectable/metastatic melanoma [23] and metastatic esophageal squamous cell carcinoma [57].